These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 28668465)

  • 21. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
    Papadopoulos N; Deutsch M; Manolakopoulos S; Bitsi C; Michalakeas H; Poulakidas H; Tsironi E; Giannouli S; Papatheodoridis GV; Koskinas J; Pectasides D
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):56-60. PubMed ID: 27669175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis.
    Zhang MY; Zhu GQ; Zheng JN; Cheng Z; Van Poucke S; Shi KQ; Huang HH; Chen FY; Zheng MH
    Expert Rev Anti Infect Ther; 2017 May; 15(5):503-513. PubMed ID: 28317397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy.
    Tamori A; Hino M; Kawamura E; Fujii H; Uchida-Kobayashi S; Morikawa H; Nakamae H; Enomoto M; Murakami Y; Kawada N
    J Gastroenterol Hepatol; 2014 Sep; 29(9):1715-21. PubMed ID: 24730465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HBV reactivation risk factors in patients with chronic HBV infection with low replicative state and resolved HBV infection undergoing hematopoietic stem cell transplantation in Korea.
    Jun CH; Kim BS; Oak CY; Lee DH; Cho E; Cho SB; Choi SK; Park CH; Joo YE; Lee JJ; Kim HJ
    Hepatol Int; 2017 Jan; 11(1):87-95. PubMed ID: 27351765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab.
    Moses SE; Lim ZY; Sudhanva M; Devereux S; Ho AY; Pagliuca A; Zuckerman M; Mufti GJ
    J Med Virol; 2006 Dec; 78(12):1560-3. PubMed ID: 17063522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation.
    Zhang MY; Zhu GQ; Shi KQ; Zheng JN; Cheng Z; Zou ZL; Huang HH; Chen FY; Zheng MH
    Oncotarget; 2016 May; 7(21):30642-58. PubMed ID: 27121321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation.
    Idilman R; Arat M
    Expert Rev Anti Infect Ther; 2011 Aug; 9(8):641-52. PubMed ID: 21819330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.
    Lee YH; Bae SC; Song GG
    Int J Rheum Dis; 2013 Oct; 16(5):527-31. PubMed ID: 24164839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in serologic markers of hepatitis B following autologous hematopoietic stem cell transplantation.
    Uhm JE; Kim K; Lim TK; Park BB; Park S; Hong YS; Lee SC; Hwang IG; Koh KC; Lee MH; Ahn JS; Kim WS; Jung CW; Kang WK
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):463-8. PubMed ID: 17382252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
    Su YC; Lin PC; Yu HC; Wu CC
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reactivation of hepatitis B virus in hematopoietic stem cell transplant recipients in Japan: efficacy of nucleos(t)ide analogues for prevention and treatment.
    Nakamoto S; Kanda T; Nakaseko C; Sakaida E; Ohwada C; Takeuchi M; Takeda Y; Mimura N; Iseki T; Wu S; Arai M; Imazeki F; Saito K; Shirasawa H; Yokosuka O
    Int J Mol Sci; 2014 Nov; 15(11):21455-67. PubMed ID: 25421241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis.
    Paul S; Saxena A; Terrin N; Viveiros K; Balk EM; Wong JB
    Ann Intern Med; 2016 Jan; 164(1):30-40. PubMed ID: 26595058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies.
    Lalazar G; Rund D; Shouval D
    Br J Haematol; 2007 Mar; 136(5):699-712. PubMed ID: 17338776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations.
    Mori S; Fujiyama S
    World J Gastroenterol; 2015 Sep; 21(36):10274-89. PubMed ID: 26420955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
    Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management.
    Lubel JS; Angus PW
    J Gastroenterol Hepatol; 2010 May; 25(5):864-71. PubMed ID: 20546439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor.
    Knöll A; Boehm S; Hahn J; Holler E; Jilg W
    J Viral Hepat; 2007 Jul; 14(7):478-83. PubMed ID: 17576389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiviral drugs in the prophylaxis of HBV infection.
    Masgala A; Nikolopoulos G; Tsiodras S; Bonovas S; Sitaras NM
    Curr Med Chem; 2012; 19(35):5940-6. PubMed ID: 22963556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prophylaxis for Hepatitis B Virus Reactivation after Allogeneic Stem Cell Transplantation in the Era of Drug Resistance and Newer Antivirals: A Systematic Review and Meta-Analysis.
    Siyahian A; Malik SU; Mushtaq A; Howe CL; Majeed A; Zangeneh T; Iftikhar S; Habib S; Zahid U; Riaz IB; Warraich Z; Faridi W; Anwer F
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1483-1489. PubMed ID: 29545185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT.
    Viganò M; Vener C; Lampertico P; Annaloro C; Pichoud C; Zoulim F; Facchetti F; Poli F; Scalamogna M; Deliliers GL; Colombo M
    Bone Marrow Transplant; 2011 Jan; 46(1):125-31. PubMed ID: 20383209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.